Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of Arni with Acei to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (Paradigm-Hf)